Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Vaxxinity Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VAXX
Nasdaq
8731
https://vaxxinity.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Vaxxinity Inc
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
- Mar 28th, 2024 1:23 pm
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
- Mar 27th, 2024 8:41 pm
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
- Mar 7th, 2024 3:32 pm
Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels
- Feb 15th, 2024 4:29 pm
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
- Feb 15th, 2024 1:00 pm
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
- Feb 13th, 2024 1:00 pm
Vaxxinity, UF Join Forces Against Neurodegenerative Diseases
- Jan 30th, 2024 5:27 pm
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
- Jan 30th, 2024 1:00 pm
Vaxxinity & UCF to Collaborate on Space Medicine Research
- Jan 19th, 2024 7:32 pm
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
- Jan 18th, 2024 1:00 pm
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 1:00 pm
The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity
- Dec 12th, 2023 2:10 pm
FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success
- Nov 20th, 2023 11:00 am
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
- Nov 13th, 2023 11:50 pm
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 8th, 2023 1:30 pm
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline
- Oct 10th, 2023 2:53 pm
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)
- Sep 7th, 2023 1:35 pm
Vaxxinity to Present at Upcoming Investor Conferences in September
- Aug 29th, 2023 12:00 pm
Vaxxinity Says UB-311 Shows Potential Advancements in Alzheimer’s Treatment
- Aug 10th, 2023 9:50 pm
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
- Aug 10th, 2023 12:00 pm
Scroll